Formulary evaluation of third-generation cephalosporins using decision analysis

Area of Science:

• Pharmacoeconomics
• Clinical Pharmacy
• Health Outcomes Research

Background:

• Formulary review processes are critical for optimizing drug selection and resource allocation.
• Third-generation cephalosporins represent a significant class of antibiotics with varying clinical and economic profiles.
• Traditional formulary review methods may lack objectivity and structured decision-making.

Purpose of the Study:

• To describe a structured, objective approach to formulary review for third-generation cephalosporins.
• To implement a decision-analysis model for evaluating and ranking antibiotic agents.
• To guide pharmacy and therapeutics (P&T) committee decisions for formulary management.

Main Methods:

• A decision-analysis model was developed and approved by the P&T committee.
• Evaluation criteria for third-generation cephalosporins were defined with assigned priority weights.
• Clinical data (spectrum, pharmacokinetics, adverse effects, stability) and financial data (acquisition cost, cost per day) were collected.
• Ranking scores were calculated by integrating clinical and financial data, weighted by importance.
• Total scores determined drug rankings for formulary inclusion.

Main Results:

• The decision-analysis process objectively evaluated cefotaxime, cefoperazone, moxalactam, ceftazidime, and ceftriaxone.
• Ceftazidime and ceftriaxone emerged as the highest-scoring agents based on the defined criteria.
• The P&T committee recommended removing cefotaxime, cefoperazone, and moxalactam from the formulary.
• Ceftazidime and ceftriaxone were recommended for inclusion, replacing the removed agents.

Conclusions:

• The structured decision-analysis model provides an objective framework for formulary review.
• This approach facilitated the rational selection of third-generation cephalosporins, favoring ceftazidime and ceftriaxone.
• Implementing such a model can lead to improved drug therapy and potential cost savings for healthcare institutions.
• Variations in criteria weighting may yield different formulary recommendations at other institutions.